Timothy C Thompson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Timothy C Thompson

Showing results (101-110 of 114) with videos related to

Pageof 12

Sort By:

Cell Reports|February 24, 2017

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 SignalingStyliani Karanika, Theodoros Karantanos, Likun Li, et al.

Nature Communications|August 29, 2020

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancerJody Vykoukal, Johannes F Fahrmann, Justin R Gregg, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019

PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate CancerBo Liu, Likun Li, Guang Yang, et al.

The Oncologist|October 29, 2002

Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancerBin S Teh, Estuardo Aguilar-Cordova, Maria T Vlachaki, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023

SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.

Science Advances|March 1, 2024

Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditionsAdam R Wolfe, Tiantian Cui, Sooin Baie, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate CancerWei Zhang, Bo Liu, Wenhui Wu, et al.

Molecular Cancer Therapeutics|June 23, 2021

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.

Cell Reports. Medicine|December 17, 2025

Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancerJody Vykoukal, Yihui Chen, Mingxin Zuo, et al.

Biomarker Research|November 10, 2024

Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.

Pageof 12

Search research articles

Showing results (101-110 of 114) with videos related to

Sort By:

Pageof 12

Cell Reports|February 24, 2017

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 SignalingStyliani Karanika, Theodoros Karantanos, Likun Li, et al.

Nature Communications|August 29, 2020

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancerJody Vykoukal, Johannes F Fahrmann, Justin R Gregg, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019

PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate CancerBo Liu, Likun Li, Guang Yang, et al.

The Oncologist|October 29, 2002

Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancerBin S Teh, Estuardo Aguilar-Cordova, Maria T Vlachaki, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023

SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth SuppressionChuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.

Science Advances|March 1, 2024

Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditionsAdam R Wolfe, Tiantian Cui, Sooin Baie, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate CancerWei Zhang, Bo Liu, Wenhui Wu, et al.

Molecular Cancer Therapeutics|June 23, 2021

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.

Cell Reports. Medicine|December 17, 2025

Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancerJody Vykoukal, Yihui Chen, Mingxin Zuo, et al.

Biomarker Research|November 10, 2024

Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.

Pageof 12